As regulatory agencies increasingly recognise real-world evidence as a complement to traditional clinical trial data, interest has grown in applying Bayesian methods across both interventional and observational research (Boulanger and Carlin (2021). A central objective in many clinical investigations is the delineation of patient subgroups that exhibit comparable disease-related characteristics (He, Belouali, Patricoski, Lehmann, Ball, Anagnostou, Kreimeyer, and Botsis (2023)). Electronic Health Records (EHR) have become an important resource for such phenotypic analyses (Hripcsak and Albers (2013)). Bayesian approaches to patient phenotyping in clinical observational studies have been limited by the computational challenges associated with applying the Markov Chain Monte Carlo (MCMC) approach to real-world data. Hubbard, Huang, Harton, Oganisian, Choi, Utidjian, Eneli, Bailey, and Chen (2019) proposed a Bayes latent class model that could be used in a general context for observational studies that use EHR data. They consider the common clinical context where gold-standard phenotype information, such as genetic and laboratory data, is not fully available. A general model of this form has high potential applicability for use in clinical decision support across disease areas for both primary and secondary clinical databases. Latent Class Analysis (LCA) is widely used when we want to identify patient phenotypes or subgroups given multivariate data (Lanza and Rhoades (2013)). A challenge in clinical LCA is the prevalence of mixed data, where we may have combinations of continuous, nominal, ordinal and count data.